Browse Categories
Search
Stay In Touch
Login
|
|
Home > All Products > Understanding the American Recovery & Reinvestment Act: NIH Life Sciences Grants and Funding for Health Information Technology
Understanding the American Recovery & Reinvestment Act: NIH Life Sciences Grants and Funding for Health Information Technology
Price: From $225.00 to $900.00
Product Options
| |
|
Understanding the American Recovery & Reinvestment Act: NIH Life Sciences Grants and Funding for Health Information Technology
President Obama signed H.R. 1, the American Recovery and Reinvestment Act of 2009 (“Recovery Act”) into law on February 17, 2009. The bill represents the largest investment in public works since the Great Depression and is an effort to revitalize an economy in crisis by infusing $787 billion into state coffers, small businesses, and struggling families.
The Recovery Act includes more than $150 billion for the healthcare industry, including $10.4 billion for the National Institute of Health (NIH) and $19.2 billion for Health Information Technology (HIT). For life sciences researchers and healthcare technologists, this means incredible opportunities for new funding. Attend this session and learn from two leading lawyers about the Recovery Act and how your business can benefit.
-
Understand NIH grant opportunities and funding for comparative effectiveness research.
-
Learn about federal funding for HIT and the ramifications of new HIT regulatory provisions for your business.
-
Navigate federal Recovery Act Web sites to view notifications and apply for Recovery Act grants.
BIO
COLIN ZICK'S practice is focused on health care and compliance issues, and often involves the intersection of those two subjects in administrative proceedings or litigation. His work has had a particular emphasis on compliance issues related to pharmaceutical and medical device companies, hospitals, practitioners (including physicians, dentists, optometrists, psychologists, veterinarians), and provider organizations. This compliance work includes helping clients establish and maintain effective compliance programs. Colin defends clients in disputes alleging kickbacks, overpayments, and billing and coding problems, and represents before various state health care licensing and regulatory entities.
KALAH AUCHINCLOSS focuses her administrative law practice on food and drug law and legislative practice, including compliance help to clients regarding Food and Drug Administration regulations. She counsels pharmaceutical and other companies on government relations strategies and public policy advocacy, and also advises health care organizations on FDA and CMS matters. Kalah's practice in addition includes general litigation and administrative law counsel. Kalah's practice emphasis reflects her extensive legal and economics research, focusing on the economics of the U.S. healthcare system, for a member of the Georgetown Law School faculty. Her knowledge of the political process reflects fundraising activities for gubernatorial, presidential, and state and local campaigns.
|
|
|
|